Research progress on signaling pathways in cirrhotic portal hypertension

Portal hypertension (PHT) is an important consequence of liver cirrhosis, which can lead to complications that adversely affect a patient’s quality of life and survival, such as upper gastrointestinal bleeding, ascites, and portosystemic encephalopathy. In recent years, advances in molecular biology have led to major discoveries in the pathological processes of PHT, including the signaling pathways that may be involved: PI3K-AKT-mTOR, RhoA/Rho-kinase, JAK2/STAT3, and farnesoid X receptor. However, the pathogenesis of PHT is complex and there are numerous pathways involved. Therefore, the targeting of signaling pathways for medical management is lagging. This article summarizes the progress that has been made in understanding the signaling pathways in PHT, and provides ideas for treatment of the disorder.

[1]  G. Meinhardt,et al.  The HMG-CoA reductase inhibitor simvastatin overcomes cell adhesion-mediated drug resistance in multiple myeloma by geranylgeranylation of Rho protein and activation of Rho kinase. , 2004, Blood.

[2]  P. Durrington,et al.  Human cholesterol metabolism and therapeutic molecules , 2007, Experimental physiology.

[3]  Weijie Wang,et al.  Rapamycin Ameliorates Inflammation and Fibrosis in the Early Phase of Cirrhotic Portal Hypertension in Rats through Inhibition of mTORC1 but Not mTORC2 , 2014, PloS one.

[4]  C. Choong,et al.  Angiopoietin-like 4 stimulates STAT3-mediated iNOS expression and enhances angiogenesis to accelerate wound healing in diabetic mice. , 2014, Molecular therapy : the journal of the American Society of Gene Therapy.

[5]  J. García‐Pagán,et al.  Terutroban, a TP‐receptor antagonist, reduces portal pressure in cirrhotic rats , 2013, Hepatology.

[6]  Mercedes Fernandez.  Molecular pathophysiology of portal hypertension , 2015, Hepatology.

[7]  M. Najimi,et al.  A role for autophagy during hepatic stellate cell activation. , 2012, Journal of hepatology.

[8]  Yongqiang Chen,et al.  The regulation of autophagy – unanswered questions , 2011, Journal of Cell Science.

[9]  Johan Auwerx,et al.  Targeting bile-acid signalling for metabolic diseases , 2008, Nature Reviews Drug Discovery.

[10]  T. Gupta,et al.  Endothelial dysfunction and decreased production of nitric oxide in the intrahepatic microcirculation of cirrhotic rats , 1998, Hepatology.

[11]  Xi-lin Du,et al.  Combined administration of propranolol + AG490 offers better effects on portal hypertensive rats with cirrhosis , 2016, Journal of gastroenterology and hepatology.

[12]  J. Bosch,et al.  Portal hypertension and its complications. , 2008, Gastroenterology.

[13]  Haiping Yang,et al.  JAK / STAT 3 signaling is required for TGF-β-induced epithelial-mesenchymal transition in lung cancer cells , 2014 .

[14]  F. Bäckhed,et al.  Gut microbiota regulates bile acid metabolism by reducing the levels of tauro-beta-muricholic acid, a naturally occurring FXR antagonist. , 2013, Cell metabolism.

[15]  C. Hellerbrand,et al.  Potent antifibrotic activity of mTOR inhibitors sirolimus and everolimus but not of cyclosporine A and tacrolimus in experimental liver fibrosis. , 2010, Journal of hepatology.

[16]  A. Lipovsky,et al.  S6K1 regulates GSK3 under conditions of mTOR-dependent feedback inhibition of Akt. , 2006, Molecular cell.

[17]  James Tomlinson,et al.  Alanine-Glyoxylate Aminotransferase-2 Metabolizes Endogenous Methylarginines, Regulates NO, and Controls Blood Pressure , 2012, Arteriosclerosis, thrombosis, and vascular biology.

[18]  Simon C Watkins,et al.  Downregulation of Endothelin-1 by Farnesoid X Receptor in Vascular Endothelial Cells , 2006, Circulation research.

[19]  R. Neubig,et al.  Novel Rho/MRTF/SRF Inhibitors Block Matrix-stiffness and TGF-&bgr;–Induced Fibrogenesis in Human Colonic Myofibroblasts , 2014, Inflammatory bowel diseases.

[20]  Yanqiao Zhang,et al.  Bile acid receptors in non-alcoholic fatty liver disease. , 2013, Biochemical pharmacology.

[21]  F. Nevens,et al.  Atorvastatin lowers portal pressure in cirrhotic rats by inhibition of RhoA/Rho‐kinase and activation of endothelial nitric oxide synthase , 2007, Hepatology.

[22]  M. Mitterhauser,et al.  Sorafenib attenuates the portal hypertensive syndrome in partial portal vein ligated rats. , 2009, Journal of hepatology.

[23]  C. Strassburg,et al.  Janus-kinase-2 relates directly to portal hypertension and to complications in rodent and human cirrhosis , 2015, Gut.

[24]  Minsuk Choi,et al.  A specific STAT3-binding peptide exerts antiproliferative effects and antitumor activity by inhibiting STAT3 phosphorylation and signaling. , 2014, Cancer research.

[25]  K. Guan,et al.  Expanding mTOR signaling , 2007, Cell Research.

[26]  P. Kang,et al.  RhoA signaling in cardiomyocytes protects against stress-induced heart failure but facilitates cardiac fibrosis , 2014, Science Signaling.

[27]  J. Nattermann,et al.  Angiotensin‐II type 1 receptor‐mediated Janus kinase 2 activation induces liver fibrosis , 2014, Hepatology.

[28]  T. A. Kerr,et al.  Molecular basis for feedback regulation of bile acid synthesis by nuclear receptors. , 2000, Molecular cell.

[29]  姉川 剛.  Defective endothelial nitric oxide synthase signaling is mediated by Rho-kinase activation in rats with secondary biliary cirrhosis , 2008 .

[30]  Jing Zhang,et al.  The vasorelaxant effect of H(2)S as a novel endogenous gaseous K(ATP) channel opener. , 2001, The EMBO journal.

[31]  Hidemi Kajimoto,et al.  Inhibition of eNOS phosphorylation mediates endothelial dysfunction in renal failure: new effect of asymmetric dimethylarginine. , 2012, Kidney international.

[32]  M. Mejías,et al.  Relevance of the mTOR signaling pathway in the pathophysiology of splenomegaly in rats with chronic portal hypertension. , 2010, Journal of hepatology.

[33]  K. Griendling,et al.  Angiotensin II cell signaling: physiological and pathological effects in the cardiovascular system. , 2007, American journal of physiology. Cell physiology.

[34]  U. Deuschle,et al.  The FXR agonist PX20606 ameliorates portal hypertension by targeting vascular remodelling and sinusoidal dysfunction. , 2017, Journal of hepatology.

[35]  Liping Peng,et al.  Sodium Ferulate Reduces Portal Pressure Through Inhibition of RhoA/Rho-Kinase and Activation of Endothelial Nitric Oxide Synthase in Cirrhotic Rats , 2015, Digestive Diseases and Sciences.

[36]  V. Balasubramaniyan,et al.  Hepatic dimethylarginine-dimethylaminohydrolase1 is reduced in cirrhosis and is a target for therapy in portal hypertension. , 2015, Journal of hepatology.

[37]  J. Reichen,et al.  Low-dose oral rapamycin treatment reduces fibrogenesis, improves liver function, and prolongs survival in rats with established liver cirrhosis. , 2006, Journal of hepatology.

[38]  M. Trauner,et al.  Bile acid transporters and regulatory nuclear receptors in the liver and beyond , 2013, Journal of hepatology.

[39]  T. Warner,et al.  Farnesoid X Receptor Ligands Inhibit Vascular Smooth Muscle Cell Inflammation and Migration , 2007, Arteriosclerosis, thrombosis, and vascular biology.

[40]  T. Sauerbruch,et al.  Intrahepatic upregulation of RhoA and Rho-kinase signalling contributes to increased hepatic vascular resistance in rats with secondary biliary cirrhosis , 2006, Gut.

[41]  Olaf Wolkenhauer,et al.  Systems biology of JAK-STAT signalling in human malignancies. , 2011, Progress in biophysics and molecular biology.

[42]  K. Iwaisako,et al.  Interleukin-17 signaling in inflammatory, Kupffer cells, and hepatic stellate cells exacerbates liver fibrosis in mice. , 2012, Gastroenterology.

[43]  Xiaoqing Zeng,et al.  Kruppel-like factor 2 inhibit the angiogenesis of cultured human liver sinusoidal endothelial cells through the ERK1/2 signaling pathway. , 2015, Biochemical and biophysical research communications.

[44]  Y. Cho,et al.  Simvastatin Suppresses Self‐Renewal of Mouse Embryonic Stem Cells by Inhibiting RhoA Geranylgeranylation , 2007, Stem cells.

[45]  D. Murry,et al.  Human Alanine-Glyoxylate Aminotransferase 2 Lowers Asymmetric Dimethylarginine and Protects from Inhibition of Nitric Oxide Production* , 2009, The Journal of Biological Chemistry.

[46]  M. Duan,et al.  Effects of Nuclear Factor-E2-related factor 2/Heme Oxygenase 1 on splanchnic hemodynamics in experimental cirrhosis with portal hypertension. , 2017, Microvascular research.

[47]  S. Antoniu.  Targeting RhoA/ROCK pathway in pulmonary arterial hypertension , 2012, Expert opinion on therapeutic targets.

[48]  T. Michel,et al.  Life history of eNOS: partners and pathways. , 2007, Cardiovascular research.

[49]  Hui-Chun Huang,et al.  Caffeine ameliorates hemodynamic derangements and portosystemic collaterals in cirrhotic rats , 2015, Hepatology.

[50]  Gordon B Mills,et al.  mTOR inhibition induces upstream receptor tyrosine kinase signaling and activates Akt. , 2006, Cancer research.

[51]  Ying-mei Tang,et al.  Celecoxib and octreotide synergistically ameliorate portal hypertension via inhibition of angiogenesis in cirrhotic rats , 2016, Angiogenesis.

[52]  Sang Gyun Kim,et al.  Rapamycin differentially inhibits S6Ks and 4E-BP1 to mediate cell-type-specific repression of mRNA translation , 2008, Proceedings of the National Academy of Sciences.

[53]  T. Sauerbruch,et al.  HSC-specific inhibition of Rho-kinase reduces portal pressure in cirrhotic rats without major systemic effects. , 2012, Journal of hepatology.

[54]  D. Heistad,et al.  Superoxide dismutase gene transfer reduces portal pressure in CCl4 cirrhotic rats with portal hypertension , 2008, Gut.

[55]  M. Mejías,et al.  Reversal of portal hypertension and hyperdynamic splanchnic circulation by combined vascular endothelial growth factor and platelet‐derived growth factor blockade in rats , 2007, Hepatology.

[56]  V. Desmet,et al.  In vivo gene transfer of endothelial nitric oxide synthase decreases portal pressure in anaesthetised carbon tetrachloride cirrhotic rats , 2002, Gut.

[57]  Chang Hwa Jung,et al.  mTOR regulation of autophagy , 2010, FEBS letters.

[58]  D. Sabatini,et al.  Growing roles for the mTOR pathway. , 2005, Current opinion in cell biology.

[59]  A. Maity,et al.  Molecular Neuroscience Review Article , 2011 .

[60]  Jin Ding,et al.  The HLF/IL-6/STAT3 feedforward circuit drives hepatic stellate cell activation to promote liver fibrosis , 2017, Gut.

[61]  Xi-lin Du,et al.  Inhibition of Janus kinase-2 signalling pathway ameliorates portal hypertensive syndrome in partial portal hypertensive and liver cirrhosis rats. , 2015, Digestive and liver disease : official journal of the Italian Society of Gastroenterology and the Italian Association for the Study of the Liver.

[62]  Min Wang,et al.  Sodium ferulate lowers portal pressure in rats with secondary biliary cirrhosis through the RhoA/Rho-kinase signaling pathway: A preliminary study , 2014, International journal of molecular medicine.

[63]  Yanqiao Zhang,et al.  FXR, a multipurpose nuclear receptor. , 2006, Trends in biochemical sciences.

[64]  S. Yonemura,et al.  Junctionally restricted RhoA activity is necessary for apical constriction during phase 2 inner ear placode invagination. , 2014, Developmental biology.

[65]  D. Guertin,et al.  Phosphorylation and Regulation of Akt/PKB by the Rictor-mTOR Complex , 2005, Science.

[66]  X. Zheng,et al.  ROCK Isoform Regulation of Myosin Phosphatase and Contractility in Vascular Smooth Muscle Cells , 2009, Circulation research.

[67]  A. B. Sukhomlinov,et al.  [Liver cirrhosis]. , 1989, Fel'dsher i akusherka.

[68]  Peter Oelkers,et al.  Bile acid transporters , 1995, Current opinion in lipidology.

[69]  Ramalinga Kuruba,et al.  Inhibition of Endothelin-1-Mediated Contraction of Hepatic Stellate Cells by FXR Ligand , 2010, PloS one.

[70]  D. Rockey,et al.  Vascular pathobiology in chronic liver disease and cirrhosis - current status and future directions. , 2014, Journal of hepatology.

[71]  A. Geerts,et al.  Rapamycin prevents mesenteric neo‐angiogenesis and reduces splanchnic blood flow in portal hypertensive mice , 2008, Hepatology research : the official journal of the Japan Society of Hepatology.

[72]  T. Roskams,et al.  Obeticholic acid, a farnesoid X receptor agonist, improves portal hypertension by two distinct pathways in cirrhotic rats , 2014, Hepatology.

[73]  K. Kaibuchi,et al.  Rho GTPase/Rho Kinase Negatively Regulates Endothelial Nitric Oxide Synthase Phosphorylation through the Inhibition of Protein Kinase B/Akt in Human Endothelial Cells , 2002, Molecular and Cellular Biology.

[74]  A. Meijer,et al.  Regulation of autophagy , 1995 .

[75]  A. Moschetta,et al.  Microbiota modification with probiotics induces hepatic bile acid synthesis via downregulation of the Fxr-Fgf15 axis in mice. , 2014, Cell reports.

[76]  R. AlvesJde.  [PORTAL HYPERTENSION]. , 1963, Hospital.

[77]  Y. Boucher,et al.  Pioglitazone decreases portosystemic shunting by modulating inflammation and angiogenesis in cirrhotic and non-cirrhotic portal hypertensive rats. , 2014, Journal of hepatology.

[78]  A. Hall,et al.  Rho GTPases and their effector proteins. , 2000, The Biochemical journal.

[79]  J. Trebicka,et al.  Statins, Rho GTPases and KLF2: new mechanistic insight into liver fibrosis and portal hypertension , 2015, Gut.